loader image
Monday, December 22, 2025
76.5 F
McAllen
- Advertisement -

COVID-19 boosters offered to anyone ages 18 and older

Translate to Spanish or other 102 languages!

Image for illustration purposes.

Mega Doctor News

- Advertisement -

RIO GRANDE VALLEY, Texas – UT Health RGV is now offering COVID-19 boosters (Pfizer-BioNTech and Moderna) to anyone ages 18 and older.

All fully vaccinated people aged 18+ can get a booster at least 6 months after their second dose of Pfizer or Moderna or at least 2 months after initial dose of Johnson & Johnson.

Community members aged 5+ can get vaccinated at the following locations:

- Advertisement -

EDINBURG

Tuesday, Nov. 30, 1-6 p.m.

HARLINGEN

Wednesday, Dec. 1, 1-6 p.m.

- Advertisement -

MISSION

Wednesday, Dec. 1, 1-6 p.m.

  • V Express Care by UT Health RGV (at H-E-B plus!), located at 2409 East Expressway 83. (By appointment only – call for available dates and times at 956-296-2935.

FOR PARENTS AND GUARDIANS OF CHILDREN AGED 5-11

  • You willreceive a call from 1-833-888-2268 (1-833-UTVACN8 ) upon scheduling your child’s appointment. Please save this phone number 
  • This lower-dose Pfizer vaccine is the only COVID-19 vaccine to be authorized and recommended for use in children aged 5-11 years and should be administered as a two-dose series, three weeks apart — just as it is for people aged 12 and up.
  • Appointments for patient’s second dose will be scheduled on-site. 
  • All children under age 18 must be accompanied by a parent or guardian.

To make an appointment, log onto uthealth.org/vaccine or call 1-833-UTRGVMD.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

6 Depression Symptoms in Midlife Linked to Almost 50% Higher Dementia Risk

In 2021, about 57 million people globally were living with dementia — an umbrella term for neurological conditions that impact a person’s cognitive skills and memory, such as Alzheimer’s disease and vascular dementia

From Patient to Hero: Isaac Garza Delivers 2,089 Smiles This Holiday Season

Mega Doctor News For Isaac Garza, it’s better to give than to receive during the...

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.
- Advertisement -
×